CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 147 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2023. The put-call ratio across all filers is 0.86 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $118,308 | -94.9% | 4,299 | -93.8% | 0.00% | -100.0% |
| Q2 2023 | $2,335,979 | +4.8% | 68,847 | +11.1% | 0.01% | -20.0% |
| Q1 2023 | $2,228,781 | +48.5% | 61,945 | +84.0% | 0.01% | +25.0% |
| Q4 2022 | $1,500,850 | +614.7% | 33,674 | +350.4% | 0.01% | +700.0% |
| Q3 2022 | $210,000 | -84.3% | 7,476 | -88.5% | 0.00% | -95.2% |
| Q1 2021 | $1,337,000 | -55.4% | 64,913 | -62.1% | 0.02% | -51.2% |
| Q4 2020 | $3,001,000 | +175.1% | 171,318 | +132.8% | 0.04% | +168.8% |
| Q3 2020 | $1,091,000 | +131.1% | 73,584 | +102.5% | 0.02% | +128.6% |
| Q2 2020 | $472,000 | – | 36,334 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 1,605,390 | $71,552,232 | 10.98% |
| Octagon Capital Advisors LP | 761,398 | $33,935,509 | 5.28% |
| TSP Capital Management Group, LLC | 269,895 | $12,029,225 | 4.50% |
| Redmile Group, LLC | 1,977,451 | $88,134,991 | 3.60% |
| COMMODORE CAPITAL LP | 495,823 | $22,099 | 3.33% |
| Tri Locum Partners LP | 176,109 | $7,849,000 | 3.18% |
| ACUTA CAPITAL PARTNERS, LLC | 115,000 | $5,125,550 | 3.15% |
| Ikarian Capital, LLC | 267,476 | $11,921,406 | 2.88% |
| RTW INVESTMENTS, LP | 3,084,215 | $137,463,463 | 2.81% |
| Eversept Partners, LP | 558,774 | $24,904,557 | 2.18% |